Title : Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients.

Pub. Date : 2011 Aug

PMID : 21773895






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 CONCLUSIONS: The results of this study suggest that FOLFIRI plus BV is a viable option in second-line treatment for mCRC refractory to first-line FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) alone, and indicate that CA125 might be a predictive biomarker for the outcome. FOLFIRI regimen mucin 16, cell surface associated Homo sapiens